Corpus ID: 39867260

Inhibition of thromboxane synthetase potentiates the antihypertensive action of an angiotensin-converting enzyme inhibitor by a prostaglandin-dependent but kinin-independent mechanism.

@article{Levens1991InhibitionOT,
  title={Inhibition of thromboxane synthetase potentiates the antihypertensive action of an angiotensin-converting enzyme inhibitor by a prostaglandin-dependent but kinin-independent mechanism.},
  author={N. Levens and D. Cot{\'e} and G. Ksander},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={1991},
  volume={259 1},
  pages={
          219-27
        }
}
Mean arterial pressure (BP) was measured in conscious, spontaneously hypertensive rats (SHR). Oral administration of the angiotensin I-converting enzyme inhibitor (ACEI) CGS 16617 significantly lowered BP. In contrast, the thromboxane synthetase inhibitor (TxSI) CGS 12970 lacked an antihypertensive action in SHR. When administered concurrently, the TxSI significantly potentiated the antihypertensive actions of the ACEI. Inhibition of thromboxane synthetase did not potentiate the… Expand
2 Citations
Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
TLDR
In patients with essential hypertension, acute administration of ridogrel reduces renal andextrarenal thromboxane A2 biosynthesis, increases renal and extrarenal prostacyclin biosynthesisation, inhibits throm boxane receptor-activated platelet aggregation, but has no effect on systemic arterial pressure. Expand
Kinins and respiratory tract diseases.
TLDR
It has been proposed that coughing during treatment with angiotensin-converting enzyme (ACE) inhibitors is linked to the action of kinins, since ACE is able to degrade Kinins, and since the effects of ACE inhibitors are reduced by kinin antagonists. Expand